Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 84 | ETA2022 | Next issue

44th Annual Meeting of the European Thyroid Association (ETA) 2022

Brussels, Belgium
10 Sep 2022 - 13 Sep 2022

Card image cap

Poster Presentations

Thyroid Cancer CLINICAL 2

ea0084ps3-14-123 | Thyroid Cancer CLINICAL 2 | ETA2022

A case of warthin-like papillary thyroid cancer. surgical decision based on eu-tirads criteria

Laszlo Kovacs Gabor , Vass Laszlo , Csapo Zsolt , Solymosi Tamas

Introduction: The Warthin-like variant of papillary thyroid cancer (WLPTC) is a rare subtype of papillary thyroid carcinoma (PTC) resembling Warthin tumours of the salivary glands, and more commonly associated with Hashimoto’s thyroiditis than other types of PTCs. The WLPTC is characterized by papillae lined by large oncocytic cells with cores having dense lymphoplasmacytic infiltrate. The prognosis of WLPTC is the same or less aggressive than that of classical PTC, but i...

ea0084ps3-14-124 | Thyroid Cancer CLINICAL 2 | ETA2022

Evaluating prognostic markers for stage migration in medullary thyroid cancer

Jager Eline , Metman Madelon , Burgerhof Hans , Kruijff Schelto , Links Thera

Background: Medullary thyroid cancer (MTC) is a rare malignancy with a variable and sometimes unpredictable disease course. To predict the course of disease more accurately at diagnosis, we introduce dynamic risk stratification by analyzing factors related to “stage migration” within the first 5 years after diagnosis.Methods: All patients diagnosed at the University Medical Center of Groningen between 1999 and 2015 were retrospectively studied....

ea0084ps3-14-125 | Thyroid Cancer CLINICAL 2 | ETA2022

Lymph nodes metastases in differentiated thyroid cancer patients: understanding their impact on the clinical outcome

Matrone Antonio , Gambale Carla , Contartese Lea , Prete Alessandro , Faranda Alessio , Molinaro Eleonora , Elisei Rossella

Background: Lymph node metastases at histology (pN1) are usual findings in differentiated thyroid cancer (DTC) patients. Their detection has an impact on the extent of surgery, the further treatments after surgery, and on the clinical outcome.Material and method: We evaluated data of 1332 consecutive DTC patients who performed the first 131I treatment between January 2010 and September 2012. According to their pN status, they were divided into...

ea0084ps3-14-126 | Thyroid Cancer CLINICAL 2 | ETA2022

The prognostic role of chromosomal gains and loss in sporadic medullary thyroid carcinoma

Ramone Teresa , Ciampi Raffaele , Casalini Roberta , Valetto Angelo , Bertini Veronica , Piaggi Paolo , Elisei Rossella , Romei Cristina

Background: Human cancer is characterized by the accumulation of somatic alterations including base substitutions, indels, structural rearrangements and somatic copy number alteration (CNA), either gain or loss, of chromosomes that can be responsible either for initiation and/or cancer progression. About 80% of Sporadic Medullary Thyroid Carcinoma (sMTC) harbor RET or RAS somatic alterations with a negative prognostic role for the presence of the RET mutation; a few s...

ea0084ps3-14-127 | Thyroid Cancer CLINICAL 2 | ETA2022

Dominant benign thyroid nodules (BTN) treated with percutaneous microwave termoablation (PMWT): an effective tool to decrease thyroid nodule volume

Criscuoli Benedetta , Manni Carlo , Alborino Salvatore , Salvatori Fabio , Losito Raffaele , Ferrara Gerardo , Elisei Daniele , Accardi Roberto , Capoccetti Francesca

Objectives: Image-guided thermal-ablation (LTA; RFA) are well established therapy options in selected BTN. PMWT is a mini-invasive technique recently applied in thyroid disease; aim of this work is investigate its effectiveness as treatment in BTN.Methods: From May 2021, 45 patients (30 F, 15 M, Aged 37-90, Mean 55,8) with BTN symptomatic/in growing, refusing/non eligible to surgery were enrolled. Inclusion criteria: nodule diameter ≥ 2 cm, mainly ...

ea0084ps3-14-128 | Thyroid Cancer CLINICAL 2 | ETA2022

Progrp as an additional screening marker in the diagnostic work up for medullary thyroid carcinoma

Schonebaum Leonoor , van Balkum Mathe , Visser W. Edward , van den Berg Sjoerd , Peeters Robin

Background: Medullary thyroid carcinoma (MTC) is a rare disease accounting for 1-3% of all thyroid carcinomas. Unfortunately, most patients present with metastasized disease: 70% with cervical lymph node metastasis and 5-10% with distant metastasis. Survival strongly correlates with stage of disease at diagnosis, illustrating the need for early diagnosis. Calcitonin is a well-established tumour marker for MTC, but its use in the screening phase is limited by a high rate of fal...

ea0084ps3-14-129 | Thyroid Cancer CLINICAL 2 | ETA2022

Hypocalcaemia secondary to lenvatinib induced-hypoparathyroidism: a case-report

Moneta Claudia , Trevisan Matteo , Colombo Carla , Giancola Noemi , Persani Luca , Fugazzola Laura , De Leo Simone

In the last decades, multi-tyrosine-kinase inhibitors (mTKI) have emerged as an effective treatment for radioiodine refractory differentiated thyroid cancer. Due to their pleiotropic mechanism of action, these drugs may cause different side effects. Hypocalcaemia has been reported in up to 35% of patients treated with mTKI, but up to date little is known about its pathophysiology and relevance. We report the case of a 78 years old woman operated on for a papillary thyroid canc...

ea0084ps3-14-130 | Thyroid Cancer CLINICAL 2 | ETA2022

The role of calcitonin wash-out in the diagnosis of small sporadic medullary cancer - case reports

Nonchev Boyan , Argatska Antoaneta , dimov rosen , Chonov Veselin , Chobankova Elena

Introduction: Medullary thyroid cancer (MTC) is a rare thyroid malignacy whоsе prognosis is highly dependent on the early diagnosis as well as on the available treatment options. Serum calcitonin represents the most sensitive test for the detection of MTC thus its measurement is strongly recommended in patients with known genetic or hereditary conditions associated with high risk of medullary hyperplasia or cancer. However, its diagnostic utility and routine clinical ...

ea0084ps3-14-131 | Thyroid Cancer CLINICAL 2 | ETA2022

Somatic BRAF V600E mutation in a patient with medullary thyroid carcinoma

Vaclavikova Eliska , Pekova Barbora , Sykorova Vlasta , Moravcova Jitka , Mastnikova Karolina , Novak Zdenek , Drozenova Jana , Chovanec Martin , Vcelak Josef , Bendlova Bela

Introduction: Medullary thyroid carcinoma (MTC) is a calcitonin-producing tumor that predominantly occurs in a sporadic form (75%) and less commonly in an inherited form. Besides activating germline mutations of the RET proto-oncogene in hereditary syndromes of MEN2, somatic RET mutations are detectable in about 50% of sporadic MTC. Further, also RAS mutations have been discovered in 30% of RET-negative tumor tissues. Other genetic alteratio...

ea0084ps3-14-132 | Thyroid Cancer CLINICAL 2 | ETA2022

Efficacy and safety of lenvatinib in a cohort of well-differentiated advanced thyroid carcinomas

Damasio Ines , Maciel Joana , Figueiredo Ana , Simoes Helder , Nunes da Silva Tiago , Simoes-Pereira Joana , Horta Mariana , Santos Rita , Donato Sara , Leite Valeriano

Introduction: Treatment of differentiated thyroid carcinoma (DTC) remains a challenge in the setting of locally advanced or metastatic disease refractory to radiodine (RAI) therapy. SELECT trial demonstrated that Lenvatinib improved progression free survival (PFS) comparing to placebo.Objective: Our aim is to report the efficacy and safety of lenvatinib in our population with aggressive DTC.Methods: We retrospectively reviewed the ...